The effect's of curcuma, black pepper, ginger on inflammatory marker and pain in the patient with knee osteoarthritis

The effects of curcuma, black pepper and ginger on prostaglandin E2 inflammatory marker and pain in patients with knee osteoarthritis in comparison with Naproxen

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017070511763N32

Enrollment

Registered

2017-10-22

Start date

2017-09-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis knee. Gonarthrosis [arthrosis of knee]

Interventions

Intervention 1: Intervention group: turmeric extract, black pepper, ginger Myxodine capsule Combination: 300 mg of curcumin, 5.7 mg of gingernol, 75.3 mg of piperin Dosage: Two capsules per day Time t

Treatment - Drugs

Intervention group: turmeric extract, black pepper, ginger Myxodine capsule Combination: 300 mg of curcumin, 5.7 mg of gingernol, 75.3 mg of piperin Dosage: Two capsules per day Time to use: Befor

Control group: naproxen tablets Dosage: Two 250 mg tablets Usage time: morning and night Duration: four weeks Construction of Iran

Eligibility

Sex/Gender

All

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: knee idiopathic Osteoarthritis; in the age range of 35-75 years; walking ability; having knee pain with a score of more than 5 according to VAS criteria. Exclusion criteria: having other knee diseases; infection of the hip joint and ankle osteoarthritis; radicular pain of lumbar spine disorders; history of physiotherapy and intra-articular injection in the last 6 months; mentall illness; neoplasmic tissues of the knee; infection and bleeding; neurological sensory and motor disorders; history of knee surgery; Obesity; consumption of aspirin and other non-steroidal anti-inflammatory drugs; pregnant women; drug use (such as opium)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
E2 prostaglandin plasma level. Timepoint: Before and after intervention. Method of measurement: Kit: Cat.No: ZB-11009S-H9648.;Pain score. Timepoint: Pre-intervention, first week, second week, third week, forth week. Method of measurement: Womac,vas questionnaire.	—

Secondary

Measure	Time frame
The amount of energy you receive. Timepoint: Before the intervention,the fourth week. Method of measurement: Food recipes questionnaire.;Weight. Timepoint: Before intervention. Method of measurement: Digital scale.;Activists level. Timepoint: Before intervention. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGorjiyan Pegah

Isfahan University of Medical Sciences

Pegahgorjiyan@yahoo.com+98 912 843 2119

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026